129075-56-5 Usage
General Description
1(2H)-Isoquinolinone, 3,4-dihydro-5-methyl- is a chemical compound with the molecular formula C10H11NO. It is an isoquinolinone derivative, and it is also known by the trade name PNU- 22394E. 1(2H)-Isoquinolinone, 3,4-dihydro-5-methyl- has been studied for its potential pharmaceutical properties, including its ability to interact with GABA receptors in the brain. It has also been investigated for its potential as an antipsychotic and anxiolytic agent. The compound's structure and properties make it a subject of interest for research in the fields of medicinal chemistry and drug development.
Check Digit Verification of cas no
The CAS Registry Mumber 129075-56-5 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,2,9,0,7 and 5 respectively; the second part has 2 digits, 5 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 129075-56:
(8*1)+(7*2)+(6*9)+(5*0)+(4*7)+(3*5)+(2*5)+(1*6)=135
135 % 10 = 5
So 129075-56-5 is a valid CAS Registry Number.
InChI:InChI=1/C10H11NO/c1-7-3-2-4-9-8(7)5-6-11-10(9)12/h2-4H,5-6H2,1H3,(H,11,12)
129075-56-5Relevant articles and documents
Synthesis of 3,4-dihydro-1(2H)-isoquinolinones
Showalter,Sercel,Stier,Turner
, p. 961 - 964 (2001)
Approaches toward the preparative-scale synthesis of target 3,4-dihydro-1(2H)-isoquinolinones 1-3 are presented. Compounds 1 and 2 were prepared via a Schmidt rearrangement on easily obtained indanone precursors, but in low overall yield. A better method
Substituted dihydroisoquinolinones and related compounds as potentiators of the lethal effects of radiation and certain chemotherapeutic agents; selected compounds, analogs and process
-
, (2008/06/13)
The invention is selected, novel, and known analogs of isoquinolinones of the formula and pharmaceutically acceptable salts thereof; novel pharmaceutical compositions; and a method for enhancing the lethal effects for tumor cells to treatment having DNA damaging activity such as ionizing radiation or with chemotherapeutic agents.
